CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: An independent, multicenter validation study

Cancer

Volumn 119, Issue 20, 2013, Pages 3696-3702

  Colombo, Chiara ^a   Miceli, Rosalba ^a   Lazar, Alexander J ^b   Perrone, Federica ^a   Pollock, Raphael E ^b   Le Cesne, Axel ^c   Hartgrink, Henk H ^d   Cleton Jansen, Anne Marie ^d   Domont, Julien ^c   Bovée, Judith V M G ^d   Bonvalot, Sylvie ^c   Lev, Dina ^b   Gronchi, Alessandro ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TEXAS   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

catenin; aggressive fibromatosis; CTNNB1; desmoid tumor; prognostic marker

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMEN; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER PROGNOSIS; CODON; CONTROLLED STUDY; CORRELATION ANALYSIS; CTNNB1 GENE; DESMOID TUMOR; FEMALE; FOLLOW UP; GENE; GENE MUTATION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; THORAX WALL; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME;

Β-CATENIN; AGGRESSIVE FIBROMATOSIS; CTNNB1; DESMOID TUMOR; PROGNOSTIC MARKER;

ADOLESCENT; ADULT; AGED; BETA CATENIN; CHILD; CHILD, PRESCHOOL; FEMALE; FIBROMATOSIS, AGGRESSIVE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84885189859     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28271     Document Type: Article

References (18)

1. Goldblum JR, Fletcher JA,. Desmoid-type fibromatoses. In:, Fletcher CDM, Unni K, Mertens F, eds. World Health Organization Pathology and Genetics, Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2002: 83-84.
2. Phillips SR, A'Hern R, Thomas JM,. Aggressive fibromatosis of the abdominal wall, limbs and limb girdles. Br J Surg. 2004; 91: 1624-1629. (Pubitemid 39619927)
3. Gronchi A, Casali PG, Mariani L, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol. 2003; 21: 1390-1397. (Pubitemid 46606421)
4. Lev D, Dhanasekaran K, Caimiao W, et al. Optimizing treatment of desmoid tumors. J Clin Oncol. 2007; 25: 1785-1791. (Pubitemid 46797962)
5. Alman BA, Li C, Pajerski ME, et al. Increased Beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol. 1997; 151: 329-334. (Pubitemid 27330053)
6. Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008; 173: 1518-1527.
7. Willert K, Nusse R,. Beta-catenin: a key mediator of Wnt signaling. Curr Opin Genet Dev. 1998; 8: 95-102. (Pubitemid 28122147)
8. Clevers H,. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127: 469-480.
9. Domont J, Salas S, Lacroix L, et al. High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer. 2010; 102: 1032-1036.
10. Le Guellec S, Soubeyran I, Rochaix P, et al. CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics. Mod Pathol. 2012; 25: 1551-1558.
11. von Mehren M, Benjamin RS, Bui MM, et al. Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012; 10: 951-960.
12. Durrleman S, Simon R,. Flexible regression models with cubic splines. Stat Med. 1989; 8: 551-561. (Pubitemid 19116001)
13. Moons KGM, Donders ART, Steyerberg EW, et al. Penalized maximum likelihood estimation to directly adjust diagnostic and prognostic prediction models for overoptimism: a clinical example. J Clin Epidemiol. 2004; 57: 1262-1270. (Pubitemid 40023146)
14. Bo N, Wang D, Wu B, et al. Analysis of β-catenin expression and exon 3 mutations in pediatric sporadic aggressive fibromatosis. Pediatr Dev Pathol. 2012; 15: 173-178.
15. Spear MA, Jennings LC, Mankin HJ, et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys. 1998; 40: 637-645. (Pubitemid 28104234)
16. Ballo MT, Zagars GK, Pollack A, et al. Desmoid tumor: prognostic factors and outcome after. surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999; 17: 158-167. (Pubitemid 29022389)
17. Merchant NB, Lewis JJ, Woodruff JM, et al. Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer. 1999; 86: 2045-2052.
18. Fiore M, Rimareix F, Mariani L, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009; 16: 2587-2593.